skip to main content

Male Breast Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardBreast CancerMale Breast CancerSCE Medical Oncology

A man has completely resected, node-positive, ER-positive, HER2-negative breast cancer and no contraindication to endocrine therapy. Which adjuvant endocrine statement best reflects ESMO guidance?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: BUse tamoxifen, considering a GnRH analogue when recurrence risk is higher

Tamoxifen is the standard adjuvant endocrine therapy for hormone-receptor-positive male breast cancer, with a GnRH analogue considered in higher-risk cases. Aromatase inhibitor monotherapy does not adequately suppress testicular oestrogen production, and neither fulvestrant nor orchidectomy is the routine adjuvant standard.

Reference: ESMO Clinical Practice Guideline: breast cancer. https://data.esmo.org/guidelines/pdf/publicassets/ESMO_2023_BreastCancer.pdf